About Guided entry of tail-anchored proteins factor CAMLG
Guided entry of tail-anchored proteins factor CAMLG (CAMLG) is a protein
from Homo sapiens identified by UniProt accession
P49069, 296 residues long.
MolForge cross-references it against 0 known binders and
58 disease associations.
Target properties
| Protein name | Guided entry of tail-anchored proteins factor CAMLG |
|---|
| UniProt accession | P49069 |
|---|
| Gene | CAMLG |
|---|
| Organism | Homo sapiens |
|---|
| Length | 296 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (58)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.57
- Parkinson disease · score 0.52
- multiple sclerosis · score 0.49
- Alzheimer disease · score 0.49
- lysosomal storage disease · score 0.49
- congenital disorder of glycosylation, type IIz · score 0.45
- body height · score 0.10
- pulmonary embolism · score 0.09
- vital capacity · score 0.05
- cancer · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P49069-F1 | alphafold | PREDICTED | 61.63 | — |
Amino-acid sequence (296 residues)
MESMAVATDG GERPGVPAGS GLSASQRRAE LRRRKLLMNS EQRINRIMGF HRPGSGAEEE SQTKSKQQDS DKLNSLSVPS VSKRVVLGDS VSTGTTDQQG GVAEVKGTQL GDKLDSFIKP PECSSDVNLE LRQRNRGDLT ADSVQRGSRH GLEQYLSRFE EAMKLRKQLI SEKPSQEDGN TTEEFDSFRI FRLVGCALLA LGVRAFVCKY LSIFAPFLTL QLAYMGLYKY FPKSEKKIKT TVLTAALLLS GIPAEVINRS MDTYSKMGEV FTDLCVYFFT FIFCHELLDY WGSEVP
Explore Guided entry of tail-anchored proteins factor CAMLG with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets